Skip to main content
Bohn Stafleu van Loghum
ZOEKEN
MENU 1 2 3 4
main-content
Top

Tip

Swipe om te navigeren naar een ander artikel

Gepubliceerd in: Quality of Life Research 10/2017

29-06-2017

The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice

Auteurs: Natalie B. Simon, Michael A. Danso, Thomas A. Alberico, Ethan Basch, Antonia V. Bennett

Gepubliceerd in: Quality of Life Research | Uitgave 10/2017

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

Purpose

To describe the prevalence, severity, and risk factors of chemotherapy-induced peripheral neuropathy (CIPN) and its impact on function and quality of life (QOL) among women treated for breast cancer in a large U.S. Community Oncology practice.

Methods

Women previously treated with taxane-based chemotherapy for early-stage breast cancer completed the EORTC QLQ–C30, QLQ–BR23, and QLQ–CIPN20. Subscales are scored 0–100; higher scores indicate greater symptom severity. Pre-specified hypotheses were tested.

Results

126 women with mean age 56.7 years (SD 11.8) were stage I–II (79.4%) or stage III (20.6%) at the time of the survey; 65.1% were White and 27.8% were Black or African American. The mean time since last taxane chemotherapy cycle was 144.9 weeks (SD 112.9). 73.0% reported having CIPN. QLQ–CIPN20 mean scores for the sensory, motor, and autonomic subscales were 18.9 (SD 23.1), 18.6 (SD 18.7), and 17.1 (SD 21.8), respectively. CIPN symptom severity was negatively correlated with global health status/QOL and physical and role functioning (range of r = −0.46 to −0.72). It was not associated with age, body mass index, diabetes, or cumulative taxane dosage, but was greater for Black or African American women (e.g., sensory, p < 0.002). CIPN sensory impairment was marginally greater for patients treated with paclitaxel compared to docetaxel (p < 0.064).

Conclusions

CIPN was prevalent in this community oncology practice and significantly impacts function and QOL. These data highlight the importance of developing methods to mitigate CIPN, and for screening for CIPN particularly among Black or African American women.
vorige artikel Acculturation matters in the relation between ambivalence over emotional expressions and well-being among Chinese American breast cancer survivors
volgende artikel Quality of life among survivors of early-stage cervical cancer in Taiwan: an exploration of treatment modality differences

Met onderstaand(e) abonnement(en) heeft u direct toegang:

BSL Podotherapeut Totaal

Binnen de bundel kunt u gebruik maken van boeken, tijdschriften, e-learnings, web-tv's en uitlegvideo's. BSL Podotherapeut Totaal is overal toegankelijk; via uw PC, tablet of smartphone.

Meer informatie
Literatuur
1.
2.
Park, S. B., Goldstein, D., Krishnan, A. V., Lin, C., Friedlander, M. L., Cassidy, J., et al. (2013). Chemotherapy-induced peripheral neurotoxicity: A critical analysis. CA: A Cancer Journal for Clinicians, 63(6), 419–436.
3.
Bakitas, M. A. (2007). Background noise: The experience of chemotherapy-induced peripheral neuropathy. Nursing Research, 56(5), 323–331. CrossRefPubMed
4.
Forsyth, P., Balmaceda, C., Peterson, K., Seidman, A. D., Brasher, P., & DeAngelis, L. M. (1997). Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. Journal of Neuro-oncology, 35, 47–53. CrossRefPubMed
5.
Hilkens, P. H., & van den Bent, M. J. (1997). Chemotherapy-induced peripheral neuropathy. Journal of the Peripheral Nervous System, 2, 350–361. PubMed
6.
Rowinsky, E. K., Chaudry, V., Cornblath, D. R., & Donehower, R. C. (1993). Neurotoxicity of taxol. Journal of the National Cancer Institute, 15, 107–115.
7.
Lipton, R. B., Apfel, S. C., Dutcher, J. P., Rosenberg, R., Kaplan, J., Berger, A., et al. (1989). Taxol produces a predominantly sensory neuropathy. Neurology, 39, 368–373. CrossRefPubMed
8.
Paice, J. A. (2009). Clinical challenges: Chemotherapy-induced peripheral neuropathy. Seminars in Oncology Nursing, 25, S8–S19. CrossRefPubMed
9.
Hausheer, F. H., Schilsky, R. L., Bain, S., Berghorn, E. J., & Lieberman, F. (2006). Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Seminars in Oncology, 33(1), 15–49. CrossRefPubMed
10.
Argyriou, A. A., Kyritsis, A. P., Makatsoris, T., & Kalofonos, H. P. (2014). Chemotherapy-induced peripheral neuropathy in adults: A comprehensive update of the literature. Cancer Management and Research, 6, 135–147. CrossRefPubMedPubMedCentral
11.
Mols, F., Beijers, T., Vreugdenhil, G., & van de Poll-Franse, L. (2014). Chemotherapy-induced peripheral neuropathy and its association with quality of life: A systematic review. Supportive Care in Cancer, 22(8), 2261–2269. CrossRefPubMed
12.
Hilkins, P. H., Verweij, J., Stoter, G., Vecht, C. J., van Putten, W. L., & van den Bent, M. J. (1996). Peripheral neurotoxicity induced by docetaxel. Neurology, 46, 104–108. CrossRef
13.
Taxol [package insert]. (2003). Princeton, NJ: Bristol-Myers Squibb.
14.
Wampler, M. A., Miaskowski, C., Hamel, K., Byl, N., Rugo, H., & Topp, K. S. (2006). The modified total neuropathy score: A clinically feasible and valid measure of taxane-induced peripheral neuropathy in women with breast cancer. The Journal of Supportive Oncology, 4(8), W9–W16.
15.
Postma, T. J., Heimans, J. J., Muller, M. J., Ossenkoppele, G. J., Vermorken, J. B., & Aaronson, N. K. (1998). Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Annals of Oncology, 9, 739–744. CrossRefPubMed
16.
Cavaletti, G., Frigeni, B., Lanzani, F., Mattavelli, L., Susani, E., Alberti, P., et al. (2010). Chemotherapy-induced peripheral neurotoxicity assessment: A critical revision of the currently available tools. European Journal of Cancer, 46, 479–494. CrossRefPubMed
17.
Shimozuma, K., Ohashi, Y., Takeuchi, A., Aranishi, T., Morita, S., Kuroi, K., et al. (2009). Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Supportive Care in Cancer, 17, 1483–1491. CrossRefPubMed
18.
Kuroi, K., Shimozuma, K., Ohashi, Y., Takeuchi, A., Aranishi, T., Morita, S., et al. (2008). A questionnaire survey of physicians’ perspectives regarding the assessment of chemotherapy-induced peripheral neuropathy in patients with breast cancer. Japanese Journal of Clinical Oncology, 38, 748–754. CrossRefPubMed
19.
Basch, E., Iasonos, A., McDonough, T., Barz, A., Culkin, A., & Kris, M. G. (2006). Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: Results of a questionnaire-based study. The Lancet Oncology, 7(11), 903–909. CrossRefPubMed
20.
Speck, R. M., Sammel, M. D., Farrar, J. T., Hennessy, S., Mao, J. J., Stineman, M. G., et al. (2013). Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer. Journal of Oncology Practice, 9(5), e234–e240. CrossRefPubMed
21.
Mols, F., Beijers, T., Lemmens, V., van den Hurk, C. J., Vreugdenhil, G., & van de Poll-Franse, L. V. (2013). Chemotherapy-induced neuropathy and its association with quality of like among 2- to 11-year colorectal cancer survivors: Results from the population-based PROFILES registry. Journal of Clinical Oncology, 31(21), 2699–2707. CrossRefPubMed
22.
Stubblefield, M. D., Burstein, H. J., Burton, A. W., Custodio, C. M., Deng, G. E., Ho, M., et al. (2009). NCCN task force report: Management of neuropathy in cancer. Journal of the National Comprehensive Cancer Network, 7(suppl 5), S-1–S-26. CrossRef
23.
Kim, H. Y., Kang, J. H., Song, C. E., & Youn, H. J. (2013). Chemotherapy-induced peripheral neuropathy and quality of life in breast cancer patients. Asian Oncology Nursing, 13(4), 222–230. CrossRef
24.
Schneider, B. P., Li, L., Radovich, M., Shen, F., Miller, K. D., Flockhart, D. A., et al. (2015). Genome-wide association studies for taxane-induced peripheral neuropathy in ECOG-5103 and ECOG-1199. Clinical Cancer Research, 21(22), 5082–5091. CrossRefPubMedPubMedCentral
25.
Candelario, N., Wongrakpanich, S., & Morginstin, M. S. (2015). Predictors of chemotherapy-induced peripheral neuropathy among breast cancer patients treated with taxanes. Journal of Clinical Oncology, 33(suppl 28S), 90. CrossRef
26.
Aaronson, N. K., Ahmadzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85, 365–376. CrossRefPubMed
27.
Sprangers, M. A., Groenvold, M., Arraras, J. I., Franklin, J., te Velde, A., Muller, M., et al. (1996). The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: First results from a three-country field study. Journal of Clinical Oncology, 14(10), 2756–2768. CrossRefPubMed
28.
Fayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. (2001). The EORTC QLQ-C30 Scoring Manual (3rd ed.). Brussles: European Organisation for Research and Treatment of Cancer.
29.
Postma, T. J., Aaronson, N. K., Heimans, J. J., Muller, M. J., Hildebrand, J. G., Delattre, J. Y., et al. (2005). The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. European Journal of Cancer, 41(8), 1135–1139. CrossRefPubMed
30.
Lumley, T., Diehr, P., Emerson, S., & Chen, L. (2002). The importance of the normality assumption in large public health data sets. Annual Review of Public Health, 23, 151–169. CrossRefPubMed
31.
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003). Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Medical Care, 41(5), 582–592. PubMed
32.
Bell, D. S. (2010). Metformin-induced vitamin B12 deficiency presenting as a peripheral neuropathy. Southern Medical Journal, 103(3), 265–267. CrossRefPubMed
33.
Eckhoff, L., Knoop, A. S., Jensen, M. B., Ejlertsen, B., & Ewertz, M. (2013). Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer. Breast Cancer Research and Treatment, 142(1), 109–118. CrossRefPubMed
34.
Alberti, P., Rossi, E., Cornblath, D. R., Merkies, I. S., Postma, T. J., Frigeni, B., et al. (2014). Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: Two sides of the same coin. Annals of Oncology, 25(1), 257–264. CrossRefPubMed
35.
Jones, S. E., Erban, J., Overmoyer, B., Budd, G. T., Hutchins, L., Lower, E., et al. (2005). Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. Journal of Clinical Oncology, 22, 5542–5551. CrossRef
36.
Argyriou, A. A., Polychronopoulos, P., Iconomou, G., Koutras, A., Kalofonos, H. P., & Chroni, E. (2005). Paclitaxel plus carboplatin-induced peripheral neuropathy. A prospective clinical and electrophysiological study in patients suffering from solid malignancies. Journal of Neurology, 252(12), 1459–1464. CrossRefPubMed
37.
Hershman, D. L., Weimer, L. H., Wang, A., Kranwinkel, G., Brafman, L., Fuentes, D., et al. (2011). Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Research and Treatment, 125(3), 767–774. CrossRefPubMed
Metagegevens
Titel
The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice
Auteurs
Natalie B. Simon
Michael A. Danso
Thomas A. Alberico
Ethan Basch
Antonia V. Bennett
Publicatiedatum
29-06-2017
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 10/2017
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-017-1635-0

Andere artikelen Uitgave 10/2017

Quality of Life Research 10/2017 Naar de uitgave

OriginalPaper

Comparison of good days and sick days of school-age children with cancer reflected through their drawings

OriginalPaper

A comprehensive questionnaire for the assessment of health-related quality of life in coeliac disease (CDQL)

Brief Communication

Examining gender-related differential item functioning of the Veterans Rand 12-item Health Survey

OriginalPaper

The impact of older person’s frailty on the care-related quality of life of their informal caregiver over time: results from the TOPICS-MDS project

OriginalPaper

Recovering from chronic myeloid leukemia: the patients’ perspective seen through the lens of narrative medicine

OriginalPaper

Relationships between environmental factors and participation in adults with traumatic brain injury, stroke, and spinal cord injury: a cross-sectional multi-center study

Version: 0.1961.0